Rezolute (RZLT) Non Operating Income (2012 - 2026)
Rezolute recorded quarterly Non Operating Income of $1.2 million in Q1 2026, down 17.42% quarter-over-quarter from $1.4 million in Q4 2025, and up 7.75% year-over-year from $1.1 million in Q1 2025.
Rezolute's Non Operating Income history runs 15 years deep, the most recent figure standing at $1.2 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 7.75% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $5.8 million (up 39.08% YoY), while the FY2025 annual figure was $5.5 million, up 179.12% from the prior year.
- Non Operating Income came in at $1.2 million for Q1 2026 at Rezolute, down from $1.4 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $1.9 million in Q2 2022 to a low of -$837000.0 in Q1 2024.
- A 5-year average of $1.0 million and a median of $1.3 million in 2024 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income jumped 1184.93% in 2022 and plunged 156.94% in 2024, its largest moves.
- Rezolute's Non Operating Income stood at $836000.0 in 2022, then soared by 53.71% to $1.3 million in 2023, then advanced by 5.06% to $1.3 million in 2024, then gained by 7.19% to $1.4 million in 2025, then decreased by 17.42% to $1.2 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $1.2 million, $1.4 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.20 Mn |
| Dec 31, 2025 | 1.45 Mn |
| Sep 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.46 Mn |
| Mar 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 1.35 Mn |
| Sep 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | 126,000.00 |
| Mar 31, 2024 | -837,000.00 |
| Dec 31, 2023 | 1.29 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Jun 30, 2023 | 1.51 Mn |
| Mar 31, 2023 | 1.47 Mn |
| Dec 31, 2022 | 836,000.00 |
| Sep 30, 2022 | 387,000.00 |
| Jun 30, 2022 | 1.88 Mn |
| Mar 31, 2022 | -454,000.00 |
| Dec 31, 2021 | -444,000.00 |
| Sep 30, 2021 | -196,000.00 |
| Jun 30, 2021 | 146,000.00 |
| Mar 31, 2021 | 1.79 Mn |
| Dec 31, 2020 | 55,000.00 |
| Sep 30, 2020 | 3,000.00 |
| Jun 30, 2020 | 5,000.00 |
| Mar 31, 2020 | 30,000.00 |
| Sep 30, 2019 | 99,000.00 |
| Jun 30, 2019 | 37,000.00 |
| Mar 31, 2019 | -2.74 Mn |
| Dec 31, 2018 | -1.00 Mn |
| Sep 30, 2018 | -803,000.00 |
| Jun 30, 2018 | -1.18 Mn |
| Mar 31, 2018 | -14,354.00 |
| Dec 31, 2017 | 32,371.00 |
| Sep 30, 2017 | 32,517.00 |
| Jun 30, 2017 | 31,688.00 |
| Mar 31, 2017 | 6,098.00 |
| Dec 31, 2016 | 1,313.00 |
| Sep 30, 2016 | 7,817.00 |
| Jun 30, 2016 | -1,180.00 |
| Mar 31, 2016 | 4,640.00 |
| Dec 31, 2015 | 543.00 |
| Sep 30, 2015 | 11,745.00 |
| Jun 30, 2015 | 54,074.00 |
| Mar 31, 2015 | -872,440.00 |
| Dec 31, 2014 | 133,458.00 |
| Sep 30, 2014 | 20,426.00 |
| Jun 30, 2014 | 224,482.00 |
| Mar 31, 2014 | -3.49 Mn |
| Dec 31, 2013 | -1.17 Mn |
| Sep 30, 2013 | -118,628.00 |
| Jun 30, 2013 | -15,463.00 |
| Mar 31, 2013 | -479,696.00 |
| Dec 31, 2012 | -37,449.00 |
| Sep 30, 2012 | -87,968.00 |
| Jun 30, 2012 | -170,308.00 |
| Mar 31, 2012 | -82,274.00 |